Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-09-20 13:36:34ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in
-
ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 TrialDaiichi Sankyo2021-09-20 13:34:15ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced
-
DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid CancersDaiichi Sankyo2021-09-20 13:29:26DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers
-
DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-09-16 13:19:50DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric
-
Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO CongressDaiichi Sankyo2021-09-07 10:01:35Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress
-
ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-08-09 10:47:51ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus
-
DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-07-08 09:52:59DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced
-
DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant GliomaDaiichi Sankyo2021-06-25 10:28:57DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:18:08DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:12:57DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
